It remains an experimental compound used in research and wellness settings, particularly in anti-aging clinics and weight management programs
This is the single best proxy for visceral fat changes and responds particularly well to the AOD 9604 mechanism
is contracted via the University of Liverpool (no personal payment) to undertake consultancy for Altimmune, AstraZeneca, Boehringer Ingelheim, Cytoki, Eli Lilly, Napp, Novo Nordisk, Menarini, Pfizer, Rhythm Pharmaceuticals, Sanofi, Saniona, Tern Pharmaceuticals, Shionogi and Ysopia
Originally developed for obesity and metabolic disorders, AOD-9604 is now marketed in the performance and wellness space for: Enhancing fat metabolism Supporting weight loss Improving lipid profiles Potential cartilage and joint repair benefits How is AOD-9604 administered
Whats happening: Sustained lipolysis is producing measurable fat loss
Developed by researchers in Australia, AOD-9604 was initially investigated as a potential anti-obesity drug due to its ability to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat accumulation)